Overview
UK rare disease drug developer's 2025 revenue missed analyst expectations
Full-year net loss narrowed, driven by lower R&D and administrative expenses
Company expects cash runway to mid-2027 after cost reductions and delayed manufacturing investments
Outlook
Company expects cash of $41.0 mln to provide runway into mid-2027
Result Drivers
R&D SPENDING SHIFT - Lower R&D expenses for alvelestat and etigilimab offset by higher costs for setrusumab manufacturing and real-world evidence programs
ADMIN COSTS DOWN - Lower accrual for annual cash bonuses and reduced professional fees drove decrease in administrative expenses
Company press release: ID:nGNXH3Sbj
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Revenue | Miss | $500,000 | $520,000 (5 Analysts) |
FY Net Income | -$41.88 mln | ||
FY Operating Income | -$40.11 mln | ||
FY Pretax Profit | -$41.88 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Mereo BioPharma Group PLC is $1.50, about 326.5% above its March 18 closing price of $0.35
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments